Methotrexate, the cornerstone of our best disease modifying regimens, is contraindicated in liver disease.
We sought to evaluate the toxicity and tolerability of the intraperitoneal/intravenous regimen by comparing the modified regimen that is used at the Moffitt Cancer Center vs the published findings of the Gynecologic Oncology Group Study 172.
Use of "m" after the regimen indicates a modified regimen.
This paper reports the results of a modified regimen for this group of patients.
Of 109 patients allocated to this modified regimen only one died in remission within 24 weeks after cranial irradiation.
However, because this postoperative CCRT regimen has the disadvantages of intolerance and poor compliance, the applicability of a modified regimen should be reevaluated.
Analysis of the anti-leukaemic effect of the modified regimen showed that up to 600 days it was at least as effective as the original more intensive regimen.
In our study, the modified regimen was shown to maintain good treatment efficacy while effectively decreasing the duration of hospital admission.
Among patients with NTM, only those with MK were treated similar to MTB patients according to a modified regimen based on ATS and IDSA guidelines [ 20].
Our modified regimen, such as "weekly paclitaxel instead of tri-weekly or tri-weekly docetaxel", also achieved a pCR rate of 65.1%%.
Since these changes, there have been no further transplant-related deaths among 11 patients who have undergone autologous stem cell transplant with the modified regimen [ 47].
